Novo Nordisk Shares Decline Amid Slowing GLP-1 Oral Prescriptions

Novo Nordisk's shares declined as prescription data for the company's GLP-1 class oral drug signaled a slowdown. Recent prescription statistics indicate that growth in this area has fallen short of expectations. Investors are particularly focused on the deceleration in market share gains for oral GLP-1 drugs compared to weekly injections. Analysts note that the slowdown in prescription data could pressure Novo Nordisk's near-term revenue expectations. The company's GLP-1 portfolio, especially in diabetes and obesity treatment, was seen as a key growth driver. However, the latest data reveals that the adoption rate of the oral formulation is lower than anticipated. Markets view this development as a negative signal for Novo Nordisk's short-term performance. The company's shares declined in intraday trading following the news. Investors are seeking more clarity on the company's GLP-1 strategy in the coming period. This is not investment advice.